Navigation Links
Valeant Announces Pricing of Senior Notes
Date:3/3/2011

ced privately negotiated purchase and sale agreement; to finance the redemption of Valeant's 4.0% convertible subordinated notes due 2013, which the Company anticipates commencing during the second quarter of 2011; and for general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.

Caution Regarding Forward-Looking Information and "Safe Harbor" StatementThis press release may contain forward-looking statements, including, but not limited to, our financing plans. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorpora
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
(Date:7/31/2014)... SUNNYVALE, Calif. , July 31, 2014  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Management Access Conference, New York, NY ... Baird Health Care Conference, New York, ... Eastern Time , Accessing Live Webcasts To access ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2
... Technologies, Inc. (Nasdaq: NTII ) and the ... have entered into a,collaboration and exclusive license agreement ... Under the terms of the agreement,Neurobiological Technologies will ... occurring protein that has been shown in animals ...
... Patient ... Population -, ... Bristol-Myers Squibb Company (NYSE: BMY ),announced today that the U.S. ... ABILIFY(R) (aripiprazole) for the,acute treatment of manic and mixed episodes associated ...
Cached Medicine Technology:Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease 2Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 9
(Date:7/31/2014)... A program for anyone looking to experience weight ... of Colorado Anschutz Health and Wellness Center (AHWC) ... transformation program. , “Extreme Weight Loss: Destination Boot ... an evidenced-based program inspired by the unscripted series “Extreme ... season, the show has participants spending their first three ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... closure in front of an enthusiastic audience of international ... Trichophytic Closure improves the appearance of a patient’s ... results of this procedure are minimally detectable in most ... technique improves on the original method of donor wound ...
(Date:7/31/2014)... You’re having a wonderful summer—sunning, gardening, enjoying BBQs ... chills and fever, headache, stiff neck, achey joints, and a ... it could actually be the first sign of Lyme ... is greater than you might think. Until last year, it ... U.S. annually. But the Centers for Disease Control and Prevention ...
(Date:7/31/2014)... San Diego, CA (PRWEB) July 31, 2014 ... by the Philadelphia Business Journal , Endo International, one ... agreed to settle thousands of transvaginal claims for $830 ... Systems Products Liability Litigation (MDL No. 2325). Melinda Helbock, ... A.P.C., said she agrees with the settlement and is ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces ... is simplified and predictable with fixed fees across the ... leading international provider of legal discovery management services for ... glaringly apparent that both the courts and legal counsel ... the complex pricing structure that plagues the litigation support ...
Breaking Medicine News(10 mins):Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3Health News:Novel Technique in Wound Closure Delivers More Discreet Results in Hair Transplant Patients 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3Health News:San Diego Product Liability Firm Provides Commentary on the Latest Developments in Transvaginal Mesh Litigation 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2
... Phoebe Prince was stalked ... staple of youth culture. Keith Deltano is using comedy to fight this serious problem., ... (PRWEB) May 24, 2010 -- Phoebe Prince ... where students are being bullied to death, is comedy the appropriate vehicle to use to address ...
... ... Food & Drug Administration’s Center for Drug Evaluation and Research (CDER) will soon ... including “SPF,” “anti-aging,” or “anti-wrinkle,” according to Benjamin L. England, former 17-year FDA ... ...
... Company ... ... Corporation announced it has joined the American Academy of Healthcare Interior Designers (AAHID) as ... the knowledge, skills and abilities of healthcare interior designers. Board Certified Healthcare Interior Design ...
... ... been named by the United States Public Health Service Commissioned Officers Association as the 2010 ... individuals who have provided significant leadership to the advancement of the health of the American ... ...
... ... Breaks , ... -- A lawsuit has been filed in the Federal District Court of the United States for ... of current and former CVS employees alleging violations of the Fair Labor Standards Act and New ...
... ... 501(c)(3) application is filed, it has a bank account, and it even has a ... What it needs now is a logo, and it has launched a nationwide contest ... Spice House, singer Gretchen Wilson, and writer Michael Z. Williamson. , ...
Cached Medicine News:Health News:Bullying Assembly Uses Comedy to Reach Students 2Health News:Bullying Assembly Uses Comedy to Reach Students 3Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 2Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 3Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 4Health News:InPro Becomes AAHID Industry Partner 2Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 2Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 3Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 4Health News:National Employee Collective and Class Action Lawsuit Filed Against CVS 2Health News:Art Contest for New Charity With A History 2Health News:Art Contest for New Charity With A History 3Health News:Art Contest for New Charity With A History 4
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
... iMRI is a neurosurgical OR that ... diagnostic tools, including iMRI, necessary to ... iMRI, neurosurgical treatments are performed in ... designed for MR compatibility and safety, ...
... Compact is the first magnetic stimulator to ... magnetic stimulation. It is designed to provide ... the diagnostic routine (at the same time, ... since you can control operations without moving ...
... X-SIZER System is a ... for thrombus removal in ... saphenous vein grafts. ... cutter and,continuous evacuation. ...
Medicine Products: